Keros Therapeutics, Inc.
KROSNasdaq
$10.64
↑ +0.3%Jul 17 close · end-of-day
Price
1Y↓ -26.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$208.9M
Enterprise Value
-$72.6M
P/E
—
P/S
6.4
P/B
0.7
EV/EBITDA
—
PEG
—
FCF Yield
-27.9%
Dividend Yield
—
Revenue (TTM)
$32.7M
Net Income (TTM)
-$85.1M
Free Cash Flow (TTM)
-$58.3M
Gross Margin
—
Operating Margin
-337.4%
Net Margin
-260.3%
ROE
-29.8%
ROIC
-2109.2%
Debt / Equity
—
Net Cash
$281.5M
Return 1Y
-25.9%
Company profile
Keros Therapeutics, Inc. focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia.
- CEO
- Jasbir S. Seehra
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 100
- Headquarters
- Massachusetts
- Website
- kerostx.com
Management & directors
- Seehra JasbirCHIEF EXECUTIVE OFFICER
- Cho EstherSVP, General Counsel
- Lerner Lorena RaquelChief Science Officer
- Regnante KeithCHIEF FINANCIAL OFFICER
Roles derived from SEC Form 4 filings.
Earnings
KROS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$32,000.00↓ -100.0%
Diluted EPS-$1.21↓ -133.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $20.1M | $0.00 | $151,000.00 | $0.00 | $243.9M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$46.7M | -$56.4M | -$114.8M | -$169.9M | -$210.8M | $67.6M |
| Net income | -$45.4M | -$58.7M | -$104.7M | -$153.0M | -$187.4M | $87.0M |
| Diluted EPS | -$2.93 | -$2.52 | -$4.15 | -$5.20 | -$5.00 | $2.30 |
| Operating cash flow | -$36.9M | -$62.1M | -$70.1M | -$124.5M | -$160.9M | $107.5M |
| Free cash flow | -$37.2M | -$63.2M | -$71.3M | -$127.0M | -$162.8M | $106.0M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | -280.5% | — | -112543.7% | — | 27.7% |
| Net margin | — | -292.3% | — | -101319.2% | — | 35.7% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $211.2M | $18.2M | $14.1M | $380,000.00 | $32,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$50.4M | -$58.7M | -$53.3M | $152.0M | -$39.8M | -$15.4M | -$29.3M | -$25.9M |
| Net income | -$45.3M | -$53.0M | -$46.0M | $148.5M | -$30.7M | -$7.3M | -$23.5M | -$23.7M |
| Diluted EPS | -$1.25 | -$1.41 | -$1.13 | $3.62 | -$0.76 | -$0.18 | -$0.38 | -$1.21 |
| Operating cash flow | -$39.8M | -$30.5M | -$46.0M | $161.2M | -$29.6M | $3.2M | -$27.3M | -$3.5M |
| Free cash flow | -$40.1M | -$30.9M | -$46.3M | $160.6M | -$30.3M | $3.1M | -$27.4M | -$3.6M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | 72.0% | -219.2% | -108.9% | -7702.6% | -80865.6% |
| Net margin | — | — | — | 70.3% | -169.0% | -51.5% | -6173.9% | -74087.5% |
Company news
Jun 26, 2026
Jun 25, 2026
May 22, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-15 | BIENAIME JEAN JACQUES | Buy | 1,000 | $10.61 | $10,610.00 | filing |
| 2026-07-01 | Prener Anne | Award | 13,786 | $0.00 | $0.00 | filing |
| 2026-06-15 | BIENAIME JEAN JACQUES | Buy | 1,000 | $10.19 | $10,190.00 | filing |
| 2026-06-11 | Newton Charles W. | Sale | 550 | $10.04 | $5,522.00 | filing |
| 2026-06-04 | Farzan Nima | Sale | 2,625 | $10.73 | $28,166.25 | filing |
| 2026-06-04 | Knowles Julius | Sale | 2,625 | $10.73 | $28,166.25 | filing |
| 2026-06-04 | Seth Alpna | Sale | 2,625 | $10.72 | $28,140.00 | filing |
| 2026-06-03 | Seth Alpna | Award | 7,142 | $0.00 | $0.00 | filing |
| 2026-06-03 | GRAY MARY ANN | Award | 7,142 | $0.00 | $0.00 | filing |
| 2026-06-03 | Farzan Nima | Award | 7,142 | $0.00 | $0.00 | filing |
| 2026-06-03 | BIENAIME JEAN JACQUES | Award | 7,142 | $0.00 | $0.00 | filing |
| 2026-06-03 | Knowles Julius | Award | 7,142 | $0.00 | $0.00 | filing |
| 2026-05-15 | BIENAIME JEAN JACQUES | Buy | 1,000 | $10.58 | $10,580.00 | filing |
| 2026-04-15 | BIENAIME JEAN JACQUES | Buy | 1,000 | $11.70 | $11,700.00 | filing |
| 2026-04-02 | Seehra Jasbir· CHIEF EXECUTIVE OFFICER | Option exercise | 55,000 | $0.30 | $16,500.00 | filing |
| 2026-03-09 | BIENAIME JEAN JACQUES | Buy | 2,000 | $11.21 | $22,420.00 | filing |
| 2026-03-09 | Newton Charles W. | Award | 13,215 | $0.00 | $0.00 | filing |
| 2026-02-19 | Seehra Jasbir· CHIEF EXECUTIVE OFFICER | Sale | 7,015 | $16.17 | $113,432.55 | filing |
| 2026-02-18 | Cho Esther· SVP, General Counsel | Sale | 4,745 | $16.35 | $77,580.75 | filing |
| 2026-02-18 | Regnante Keith· CHIEF FINANCIAL OFFICER | Sale | 4,739 | $16.35 | $77,482.65 | filing |
| 2026-02-18 | Lerner Lorena Raquel· Chief Science Officer | Sale | 3,873 | $16.35 | $63,323.55 | filing |
| 2025-11-21 | Knowles Julius | D | 191,527 | $17.75 | $3.4M | filing |
| 2025-11-21 | GORDON CARL L | D | 140,057 | $17.75 | $2.5M | filing |
| 2025-11-21 | ORBIMED ADVISORS LLC | D | 140,057 | $17.75 | $2.5M | filing |
| 2025-11-21 | Knowles Julius | D | 130,494 | $17.75 | $2.3M | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.